Dual Anti-HER2 Targeting in the Adjuvant ALTTO ph III Trial

Speaker: Giuseppe Curigliano

In this ESMO expert interview, G. Curigliano explains why in term of scientific rationale the ALTTO was an exciting trial. He elaborates on study results which are unfortunately negative and argues that additional translational research studies can help in term of data interpretation.

Discussion Points

ALTTO Phase 3 trial results: First results comparing one year of anti-HER2 therapy with single therapy vs sequence or combination therapy in the adjuvant setting for HER2-positive early breast cancer.

  • Brief summary of results
  • Implications for clinical practice
  • Specific warnings to practitioners
  • Need for further research in the field